VasoRx

VasoRx, Inc. is a biopharmaceutical company established in 2018, operating from San Diego, California, to develop RNA-based therapeutics for severe cardiovascular and cardiopulmonary diseases. The company's foundation is built upon a groundbreaking discovery in 2014 by Professors Robert Langer and Dan Anderson from MIT, who developed a unique lipid nanoparticle (LNP) platform capable of specifically delivering RNA to the vascular endothelium. VasoRx holds an exclusive global license for this technology, which it has further developed.

The company was co-founded by a team of distinguished scientists and experienced biopharmaceutical professionals, including Dr. Krisztina Zsebo, who serves as CEO, and scientific advisory board members Dr. Michael Simons, Professor Robert Langer, and Professor Daniel Anderson. Dr. Zsebo brings 39 years of industry experience, including her time as CEO of Celladon Corporation, which she took public. The founders' expertise in RNAi/LNP technology and cardiovascular disease forms the scientific core of the company's mission. Since its inception, VasoRx has secured funding through grants and angel investments, including a notable $5.4 million from Open Philanthropy in April 2018, followed by subsequent investments to advance their research.

VasoRx's business model is centered on the research and development of proprietary RNA therapies. The company aims to address the underlying causes of vascular diseases by targeting the molecular pathways that control vascular remodeling, chronic inflammation, and fibrosis. Its core technology utilizes novel polymeric nanoparticles to deliver RNAi and mRNA to endothelial cells with high efficiency, which has been a significant challenge in the field. This allows for the silencing of specific genes that drive disease progression. The company's revenue generation will likely depend on future partnerships, licensing agreements, and the eventual commercialization of its therapeutic products upon successful clinical trials and regulatory approval.

The product pipeline includes two primary candidates, VSR03 and VSR05. VSR03 is an intravenous therapy designed to treat pulmonary hypertension by reprogramming lung vascular cells, administered at an outpatient clinic every 30 days. VSR05 targets atherosclerosis by delivering LNPs to coronary and carotid vascular cells to induce regression and stabilization of plaques. Pre-clinical studies in animal models have demonstrated the potential to reverse vascular changes in pulmonary hypertension and significantly reduce the volume of atherosclerotic plaques. This therapeutic approach targets the endothelial-to-mesenchymal transition, a key process in the pathology of these conditions.

Keywords: RNA therapeutics, cardiovascular disease, lipid nanoparticles, pulmonary hypertension, atherosclerosis, gene silencing, drug delivery, endothelial cells, biopharmaceutical, vascular remodeling